New acne pill enters first human tests

NCT ID NCT06989840

Recruiting now Symptom relief Sponsor: Sagimet Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called TVB-3567 in 128 healthy adults, some with acne. The main goal is to check safety and how the body processes the drug, not yet whether it works. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TVB-3567 (oral capsule)
What this could lead to: If safe and effective, this could lead to a new oral treatment for acne.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not on curing acne. It may fail to show benefit or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACNE

Contacts and locations

Locations

Celerion, Inc.
COMPLETED

Tempe, Arizona, 85283, United States
Nucleus Network
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.